Internal Medicine, Endocrinology, Diabetes, & Metabolism · Janesville, WI
NPI
1831297308
Since 2006
Specialty
Internal Medicine, Endocrinology, Diabetes, & Metabolism
Code 207RE0101X
Group practices
1
Medicare group memberships
Hospitals
2
Hospital affiliations
3524 E Milwaukee St
Janesville, WI, 53546
Phone (608) 756-7100
Groups this clinician bills Medicare through
Medicare paid, 2024
$38K
679 services
Medicare patients, 2024
377
Average age 70
Drug cost, 2024
$3.7M
6,183 prescriptions
Company payments, 2024
$101
From 3 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Patrick P Litonjua was code 99214 (office e&m - established), 360 times for 196 patients. In total Patrick P Litonjua billed 679 services in 23 codes, and Medicare paid $38K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2012-09-10.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 360 | 196 | $66.97 | $24K |
| 99213 Office E&M - Established | Office | 152 | 136 | $42.87 | $6,517 |
| 99204 Office E&M - New | Office | 49 | 49 | $90.55 | $4,437 |
By year: 2022 $37K for 629 services; 2023 $37K for 649 services; 2024 $38K for 679 services.
Medicare prescription drug claims, 2024
In 2024, the drug Patrick P Litonjua prescribed most often to Medicare patients was Ozempic (Semaglutide), with 521 prescriptions and refills. In total Patrick P Litonjua wrote 6,183 Medicare prescriptions that cost $3.7M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Ozempic Semaglutide | 521 | 832 | 113 | $798K |
| Lantus Solostar Insulin Glargine,hum.Rec.Anlog | 487 | 1,066 | 130 | $110K |
| Levothyroxine Sodium Generic | 360 | 971 | 85 | $3,540 |
| Trulicity Dulaglutide | 352 | 597 | 86 | $584K |
| Metformin Hcl Er Metformin Hcl | 332 | 824 | 83 | $5,093 |
| Jardiance Empagliflozin | 292 | 621 | 66 | $357K |
| Metformin Hcl Generic | 256 | 694 | 66 | $2,928 |
| Mounjaro Tirzepatide | 237 | 374 | 51 | $398K |
| Humalog Kwikpen U-100 Insulin Lispro | 185 | 428 | 53 | $92K |
| Methimazole Generic | 175 | 390 | 47 | $2,772 |
| Tresiba Flextouch U-100 Insulin Degludec | 139 | 281 | 35 | $135K |
| Novolog Flexpen Insulin Aspart | 129 | 273 | 37 | $48K |
| Nano 2nd Gen Pen Needle Pen Needle, Diabetic | 119 | 322 | 48 | $14K |
| Humulin R U-500 Kwikpen Insulin Regular, Human | 118 | 195 | 24 | $266K |
| Atorvastatin Calcium Generic | 117 | 295 | 28 | $959 |
Brand drugs: 3,714 claims; generic drugs: 1,911 claims.
Money and other things of value reported by the companies
In 2024, drug and medical device companies paid Patrick P Litonjua $101 ($101 in general payments such as food, travel and fees) from 3 companies. The largest payer was Boehringer Ingelheim Pharmaceuticals, Inc. with $47.23.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.